The safety of drugs used in acid-related disorders and functional gastrointestinal disorders
- PMID: 20951916
- PMCID: PMC3117659
- DOI: 10.1016/j.gtc.2010.08.009
The safety of drugs used in acid-related disorders and functional gastrointestinal disorders
Abstract
Medicines are frequently used in the management of acid-related disorders and functional gastrointestinal disorders. With the exception of complicated peptic ulcer disease, these disorders are not associated with appreciable mortality. Drug treatments have consequently been held to the highest standards of safety. Some medicines have been withdrawn or restricted based on assessments and perceptions of risk. However, the risk of serious toxicity is low for most of the agents discussed in this article. Assessments are made of the safety and adverse-event profiles of certain drug classes and, where appropriate, individual medicines. For conditions with a low risk of mortality or serious morbidity, clinicians need to balance the risks of potential adverse events with the anticipated benefits of a successful outcome of specific drug treatment.
Copyright © 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Proton pump inhibitors--their pharmacological impact on the clinical management of acid-related disorders.Arzneimittelforschung. 2009;59(6):271-82. doi: 10.1055/s-0031-1296397. Arzneimittelforschung. 2009. PMID: 19634508 Review.
-
The Clinician's Guide to Proton Pump Inhibitor Related Adverse Events.Drugs. 2019 May;79(7):715-731. doi: 10.1007/s40265-019-01110-3. Drugs. 2019. PMID: 30972661 Review.
-
Proton pump inhibitors--uncommon adverse effects.Aust Fam Physician. 2011 Sep;40(9):705-8. Aust Fam Physician. 2011. PMID: 21894279
-
Comparison of proton pump inhibitors and histamine 2 receptor antagonists for stress ulcer prophylaxis in the intensive care unit.Sci Rep. 2021 Sep 16;11(1):18467. doi: 10.1038/s41598-021-98069-7. Sci Rep. 2021. PMID: 34531488 Free PMC article.
-
Does PPI therapy predispose to Clostridium difficile infection?Nat Rev Gastroenterol Hepatol. 2009 Sep;6(9):555-7. doi: 10.1038/nrgastro.2009.128. Nat Rev Gastroenterol Hepatol. 2009. PMID: 19713988
Cited by
-
A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors.Adv Ther. 2017 May;34(5):1070-1086. doi: 10.1007/s12325-017-0532-9. Epub 2017 Apr 20. Adv Ther. 2017. PMID: 28429247 Free PMC article. Review.
-
The dose of omeprazole required to achieve adequate intraesophageal acid suppression in patients with gastroesophageal junction specialized intestinal metaplasia and Barrett's esophagus.Dig Dis Sci. 2013 Aug;58(8):2253-60. doi: 10.1007/s10620-013-2763-1. Epub 2013 Jul 4. Dig Dis Sci. 2013. PMID: 23824407
-
Proton pump inhibitors: impact on glucose metabolism.Endocrine. 2013 Feb;43(1):22-32. doi: 10.1007/s12020-012-9755-3. Epub 2012 Aug 12. Endocrine. 2013. PMID: 22886351 Review.
-
Descending duodenal adenocarcinoma treated with pembrolizumab resulting in complete clinical response: A case report and literature review.World J Gastrointest Oncol. 2025 Jun 15;17(6):107568. doi: 10.4251/wjgo.v17.i6.107568. World J Gastrointest Oncol. 2025. PMID: 40547150 Free PMC article.
-
Supplement With Calcium or Alendronate Suppresses Osteopenia Due to Long Term Rabeprazole Treatment in Female Mice: Influence on Bone TRAP and Osteopontin Levels.Front Pharmacol. 2020 May 13;11:583. doi: 10.3389/fphar.2020.00583. eCollection 2020. Front Pharmacol. 2020. PMID: 32477111 Free PMC article.
References
-
- Pantoprazole [package insert] Philadelphia: Wyeth Pharmaceuticals; 2007.
-
- Omeprazole [package insert] Wilmington, DE: AstraZeneca LP; 2008.
-
- Esomeprazole [package insert] Wilmington, DE: AstraZeneca LP; 2008.
-
- Lansoprazole [package insert] Lake Forest, IL: Takeda Pharmaceuticals America Inc; 2009.
-
- Rabeprazole [package insert] Titusville, NJ: Eisai Co Ltd; 2009.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources